|
CURRENT PUBLICATIONS
Mesenchymal Stem Cells Facilitate the Derivation of Human Embryonic Stem Cells from Cryopreserved Poor-quality Embryos
The efficiency of human embryonic stem cells derivation from frozen poor-quality embryos is low, but this study attempted to optimize embryo survival and hESC derivation. [Human Reproduction]
Microsphere-based Tracing and Molecular Delivery in Embryonic Stem Cells
This paper describes a polystyrene microsphere-based system designed to efficiently deliver biological materials into both undifferentiated and differentiating embryonic stem cells. [Biomaterials]
Naturally Immortalized Mouse Embryonic Fibroblast Lines Support Human Embryonic Stem Cell Growth
This study reports the derivation of three new mouse embryonic fibroblast cell lines, MEFLU-M, MEFLU-T, and MEFLU-TB, with different properties regarding growth and support for undifferentiated hESCs. [Cloning and Stem Cells]
BMP Signaling Pathway is Required for Commitment of C3H10T1/2 Pluripotent Stem Cells to the Adipocyte Lineage
In this article, the researchers show that both bone morphogenetic protein (BMP)2 and BMP4 can induce commitment of C3H10T1/2 pluripotent stem cells into adipocytes. [Proceedings of the National Academy of Sciences]
Repair of Acute Myocardial Infarction with Induced Pluripotent Stem Cells Induced by Human Stemness Factors
In this study, fibroblasts transduced with human stemness factors OCT3/4, SOX2, KLF4, and c-MYC converted into an embryonic stem cell-like phenotype and demonstrated the ability to spontaneously assimilate into pre-implantation host morula via diploid aggregation, unique to bona fide pluripotent cells. [Circulation]
|
|
INDUSTRY NEWS
Connexon Creative Launches Cord Blood News
Cord Blood News is a weekly e-newsletter that keeps members of the cord blood community informed by providing the latest news from all areas of the field, including its science, research, policy, and business.
ImmunoCellular Therapeutics Retains Services of Torrey Pines Institute for Molecular Studies and Renowned Immunologist to Evaluate Lead Product Candidate
ImmunoCellular Therapeutics, Ltd. announced recently that it has retained the services of the Torrey Pines Institute for Molecular Studies in San Diego, CA, to evaluate the immunogenicity of peptides to target cancer stem cells relating to the Company's lead product candidate ICT-121.
Yissum Licenses Stem Cell Technologies for Spinal Therapy to TheraCell, Inc.
Yissum Research Development Company of the Hebrew University of Jerusalem Ltd., recently announced that it has licensed a novel package of stem cell related technologies to TheraCell, Inc., which will further develop and commercialize the technology for advanced regenerative medicine procedures such as spinal fusion.
Case Western Reserve University Receives $5M from Third Frontier Commission for the Center for Stem Cell and Regenerative Medicine
The Center for Stem Cell and Regenerative Medicine, comprised of Case Western Reserve University, Cleveland Clinic, University Hospitals, and Athersys, Inc. has received $5 million from Ohio's Third Frontier Commission under the Research Commercialization Program.
UK to Channel EUR $21M into Regenerative Medicine
The UK's Office for Life Sciences will invest EUR $21M into the development of stem cell therapies via its "Life Sciences Blueprint" program.
Canadian Biotechnology Feels the Pinch as Funds Dry Up
Canada will lose up to 7,000 high-skilled research and development jobs within one year if short-term financing cannot be obtained, results from the most recent BIOTECanada survey show
Cellular Dynamics International In-Licenses Key Patent Portfolio for Using Stem Cell-Derived Cells in Drug Testing
Cellular Dynamics International recently announced that it has exclusively in-licensed a US-issued patent portfolio on optimizing the stem cell differentiation selection process and on using heart cells in drug testing.
Cytori Expands Patent Protection for the Celution(R) System and Uses for Adipose Derived Stem and Regenerative Cells
Cytori Therapeutics, Inc. recently received a Notice of Allowance from the U.S. Patent and Trademark Office related to uses of the Celution(R) System for the treatment of bone related disorders.
|
|
|
This email was sent by: Connexon Creative
400-570 W. 7th Avenue Vancouver, British Columbia V5Z 1B3 Canada |
|
|
